Zealand Pharma and Generate Biomedicines have entered a collaboration to develop multispecific protein therapeutics for obesity and metabolic diseases using AI technology. Generate will lead early research with its generative AI platform, while Zealand Pharma will handle clinical development and commercialization. The deal includes $30 million upfront, up to $35 million in early milestones, and nearly $1.2 billion in total milestones plus royalties. This partnership aims to expand Zealand Pharma's drug development capabilities beyond peptides and accelerate innovative treatments for metabolic health.
Zealand Pharma and Generate Biomedicines' collaboration on AI-engineered protein therapeutics for metabolic diseases is notable amid a health sector where 28 of 128 US stocks rose and 100 fell on Pluang today. Among these, Heron Therapeutics Inc (HRTX) traded at USD 0.39 with a 5.32% decline and a typical hold time of 36 days, Nuwellis Inc (NUWE) at USD 0.64 down 5.27% with 27 days hold, and 10X Genomics Inc (TXG) at USD 71.71 down 4.63% with a 92-day hold and 100% buy order activity. This snapshot is as of Oct 14, 2026, 03:02 WIB.
Applied Materials projects sustained demand for its chipmaking equipment driven by AI infrastructure growth, expecting faster spending on wafer fab equipment through 2030. The company aims to increase its market share by over 2 percentage points from...
Gordon Haskett Capital Corporation set a $105 price target for Ollie's Bargain Outlet, suggesting an 18.1% upside from its current price around $89. The company’s board approved an additional $500 million share repurchase authorization, increasing to...
FRUIT Holdings, Inc. introduced PAVE, a new protocol designed to allow AI systems to call on human judgment and authority when needed. This approach ensures that human input retains its value, authority, and attribution within AI workflows, addressin...
AngioDynamics reported a 6.9% revenue increase to $80.9 million and a narrowed adjusted loss of 4 cents per share for Q1 fiscal 2027, with strong Med Tech sales growing 13.2%. Despite beating earnings expectations and improved gross margin, the stock...
Nathan's Famous, Inc. is proposed to be sold to Smithfield Foods, Inc. with shareholders set to receive $102 in cash per share. The law firm Kahn Swick & Foti, led by former Louisiana Attorney General Charles C. Foti, Jr., is investigating whether th...
